American journal of clinical pathology · 2012
Clinical and pathologic features of secondary acute promyelocytic leukemia.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Duffield Amy S, Aoki Joseph, Levis Mark, Cowan Kathleen, Gocke Christopher D, Burns Kathleen H, Borowitz Michael J, Vuica-Ross Milena
Аннотация
Acute promyelocytic leukemia (APL) is a relatively common form of acute myeloid leukemia (AML) that has an excellent prognosis. In contrast, secondary acute myeloid leukemias, including therapy-related AML and AML with myelodysplasia-related changes, have a relatively poor prognosis. We identified 9 cases of APL at our institution in which there was a history of chemotherapy, radiotherapy, chronic immunosuppression, or antecedent myelodysplastic syndrome. The clinical and pathologic findings in these cases of secondary APL were compared with the clinical and pathologic findings in cases of de novo APL. We found that secondary and de novo APL had abnormal promyelocytes with similar morphologic and immunophenotypic features, comparable cytogenetic findings, comparable rates of FMS-like tyrosine kinase mutations, and similar rates of recurrent disease and death. These data suggest that secondary APL is similar to de novo APL and, thus, should be considered distinct from other secondary acute myeloid neoplasms.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overAntigens, CDBiomarkers, TumorBone Marrow CellsChromosome AberrationsCombined Modality TherapyFemaleFlow CytometryGranulocyte Precursor CellsHumansImmunocompromised HostImmunophenotypingLeukemia, Myeloid, AcuteMaleMarylandMiddle AgedMutationMyelodysplastic SyndromesNeoplasms, Second PrimaryPrognosisProtein-Tyrosine KinasesSurvival RateYoung Adult